Aryl aniline β2 adrenergic receptor agonists
View Patent ↗The invention provides novel β 2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β 2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.
1. A hydrochloride salt of N-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(R)-2-hydroxy-2-(8-hydroxy-2(1H)-quinolinon-5-yl)ethylamine.
2. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically-acceptable carrier.
3. The pharmaceutical composition of claim 2 , wherein the composition is formulated for administration by inhalation.
4. The pharmaceutical composition of claim 2 , wherein the composition further comprises a therapeutically effective amount of a steroidal anti-inflammatory agent.
5. The pharmaceutical composition of claim 2 , wherein the composition further comprises a therapeutically effective amount of one or more therapeutic agents selected from the group consisting of a steroidal anti-inflammatory agent, a muscarinic receptor antagonist agent, a phosphodiesterase inhibitor agent, an immunoglobulin antibody, a leukotriene antagonist agent, a cytokine antagonist agent, a protease inhibitor, cromolyn sodium, nedocromil sodium, and sodium cromoglycate.
6. A method of agonizing β 2 adrenergic receptor activity in a mammal, the method comprising administering to the mammal, a therapeutically effective amount of a pharmaceutical composition of claim 2 .
7. The method of claim 6 , wherein the disease or condition is a pulmonary disease.
8. The method of claim 7 wherein the pulmonary disease is asthma or chronic obstructive pulmonary disease.
9. The method of claim 6 wherein the disease or condition is selected from the group consisting of pre-term labor, neurological disorders, cardiac disorders, and inflammation.
10. The method of claim 6 further comprising administering a therapeutically effective amount of a steroidal anti-inflammatory agent.
11. The method of claim 6 further comprising administering a therapeutically effective amount of one or more therapeutic agents selected from the group consisting of a steroidal anti-inflammatory agent, a muscarinic receptor antagonist agent, a phosphodiesterase inhibitor agent, an immunoglobulin antibody, a leukotriene antagonist agent, a cytokine antagonist agent, a protease inhibitor, cromolyn sodium, nedocromil sodium, and sodium cromoglycate.